Bank of America Securities analyst Travis Steed has maintained their bullish stance on ABT stock, giving a Buy rating yesterday.
Travis Steed has given his Buy rating due to a combination of factors that highlight Abbott Laboratories’ promising growth potential. The company recently announced an earlier-than-expected CE Mark for its Volt system, a significant development in the field of pulse field ablation (PFA) for atrial fibrillation treatment. This early approval allows Abbott to commence commercial PFA cases in the EU, positioning the company to expand its market presence and address concerns regarding its electrophysiology (EP) growth outlook.
Furthermore, the Volt system has demonstrated impressive initial study results, with high acute effectiveness and relatively low adverse event rates. The continued rollout and adoption of PFA technology, particularly in the US market where penetration is expected to be higher, further supports the positive outlook. With the US approval anticipated in early 2026 and ongoing trials showing promising progress, Abbott Laboratories is well-positioned for growth, justifying the Buy rating.
According to TipRanks, Steed is a 4-star analyst with an average return of 8.8% and a 59.81% success rate. Steed covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Abbott Laboratories, and Dexcom.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $140.00 price target.